Wells Fargo & Company Biovie Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.4 - $0.56 $1,554 - $2,176	-3,887 Reduced 41.41%	5,499 $2,000
Q1 2024 May 10, 2024	BUY	$0.53 - $1.89 $413 - $1,476	781 Added 9.08%	9,386 $4,000
Q4 2023 Feb 09, 2024	BUY	$1.22 - $5.24 $2,934 - $12,602	2,405 Added 38.79%	8,605 $10,000
Q3 2023 Nov 13, 2023	SELL	$2.75 - $5.17 $2,043 - $3,841	-743 Reduced 10.7%	6,200 $21,000
Q2 2023 Aug 15, 2023	BUY	$4.09 - $8.29 $5,595 - $11,340	1,368 Added 24.54%	6,943 $29,000
Q1 2023 May 12, 2023	SELL	$4.89 - $10.53 $7,183 - $15,468	-1,469 Reduced 20.85%	5,575 $45,000
Q4 2022 Feb 13, 2023	BUY	$3.86 - $42.0 $16,825 - $183,078	4,359 Added 162.35%	7,044 $54,000
Q3 2022 Nov 14, 2022	BUY	$1.38 - $25.6 $2 - $51	2 Added 0.07%	2,685 $7,000
Q2 2022 Aug 12, 2022	BUY	$1.44 - $5.04 $2 - $10	2 Added 0.07%	2,683 $4,000
Q1 2022 May 16, 2022	BUY	$2.74 - $5.65 $7,263 - $14,978	2,651 Added 8836.67%	2,681 $13,000
Q3 2021 Nov 15, 2021	BUY	$6.69 - $16.93 $107 - $270	16 Added 114.29%	30 $0
Q4 2020 Feb 09, 2021	BUY	$7.85 - $17.32 $109 - $242	14 New	14 $0

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $92M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.